Biopharmaceutical company Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) said on Friday that NHS England has implemented the use of Evkeeza (evinacumab) for eligible adults and adolescents with homozygous familial hypercholesterolemia (HoFH).
This decision follows positive guidance from the National Institute for Health and Care Excellence (NICE).
Evkeeza, a monoclonal antibody that inhibits the ANGPTL3 protein, is designed to lower levels of LDL-C, or bad cholesterol. The drug will be available at seven hospital trusts in England, providing a significant treatment option for patients with this rare and serious condition.
HoFH is a genetic disorder characterised by extremely high levels of LDL-C, which can lead to premature heart disease.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval